General
publicado em 04/11/2012 às 07h00:00
   Dê o seu voto:

Instituto Vital Brazil will produce two more drugs for SUS

Idea is that in five years, the drugs used to treat rheumatoid arthritis are wholly produced in the country

 
font size
A-
A+

Some pieces of information on this page may have been automatically translated. Makernews is not responsible for the irregularities resulting from these translations. When in doubt,      consult the original text.



The Instituto Vital Brazil signed two terms of engagement with the Ministry of Health this week for the national production of drugs etanercept and rituximab, used in the treatment of rheumatoid arthritis. The goal is to stimulate the production of medicines in Brazil. The idea is that in five years, these drugs are produced entirely in Brazil.

The etanerpecte and rituximab (both biological products) will be produced by Instituto Vital Brazil (in partnership with the Brazilian Pharmaceutical Biotechnology - Bionovis). The two drugs are injected. The presentations will be manufactured etanercept 25mg and 50mg. Already rituximab, which is also used in the treatment of cancer, will have presentations and 100mg/10ml 500mg/50ml.

These medicines are of high strategic complexity, which today are distributed by Unified Health System (SUS), hence the importance of its nationalization. The first deliveries of these products are planned for 2014, says Antonio Werneck, president of Vital Brazil Institute.

Rheumatoid arthritis is an autoimmune disease characterized by inflammation of the joints and can lead to functional impairment of affected patients.

Instituto Vital Brazil is a science and technology company of the government of the state of Rio de Janeiro. It is one of 21 official laboratories Brazilians and one of four providers antisera against the venom of poisonous animals for the Ministry of Health

Source: Isaude.net
   Palavras-chave:   Instituto Vital Brazil    SUS    Medicine    Biotechnology    Rio de Janeiro   
  • Share this pageShare this page
  • Share this pageCorrect
  • ShareShare
  • AlertAlert
Reduced link: 
  • You are recommending this story: Instituto Vital Brazil will produce two more drugs for SUS
  • Fill in the following form to send your recommendation to your friend:

  • You are suggesting a correction for this story: Instituto Vital Brazil will produce two more drugs for SUS


Receba notícias do iSaúde no seu e-mail de acordo com os assuntos de seu interesse.
Seu nome:
Seu email:
Desejo receber um alerta com estes assuntos:
Instituto Vital Brazil    SUS    medicine    biotechnology    Rio de Janeiro   
Comments:
Comment
Leave your comment
Close
(Required fields are marked with an *)

(Your email address will never be published or shared.)

Enter the letters and numbers below and click in the button "send"

  • Twitter iSaúde
advertising
Informe Saúde printed version

Recommend the portal
Close [X]
  • You are recommending this story: http://www.isaude.net
  • Fill in the following form to send your recommendation to your friend:

RSS news from the portal  iSaúde.net
Get the newsletter of the portal  iSaúde.net
Recommend the portal iSaúde.net
News from  iSaúde.net in your blog or website.
Get news on the subject of your interest.
© 2000-2011 www.isaude.net Todos os direitos reservados.